Randomized Phase 3 Trial of Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer and No Prior Chemotherapy

BACKGROUND: Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) post-chemotherapy. Many mCRPC patients never receive chemotherapy and thus cannot benefit from abiraterone acetate; we evaluated this agent i...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Ryan, Charles J., Smith, Matthew R., de Bono, Johann S., Molina, Arturo, Logothetis, Christopher J., de Souza, Paul, Fizazi, Karim, Mainwaring, Paul, Piulats, JM, Ng, Siobhan, Carles, Joan, Mulders, Peter F.A., Basch, Ethan, Small, Eric J., Saad, Fred, Schrijvers, Dirk, Van Poppel, Hendrik, Mukherjee, Som D., Suttmann, Henrik, Gerritsen, Winald R., Flaig, Thomas W., George, Daniel J., Yu, Evan Y., Efstathiou, Eleni, Pantuck, Allan, Winquist, Eric, Higano, Celestia S., Park, Youn, Kheoh, Thian, Griffin, Thomas, Scher, Howard I., Rathkopf, Dana E.
格式: Artigo
語言:Inglês
出版: 2012
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC3683570/
https://ncbi.nlm.nih.gov/pubmed/23228172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1209096
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍